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Estrogenic and antiandrogenic endocrine-
disrupting compounds (EDCs) cause a 
wide spectrum of developmental and fertil-
ity detrimental effects [for review, see Sharpe 
(2003) and Gray et al. (2001), respectively]. 
Most studies have used high doses of a single 
compound and short exposure periods, gen-
erally during the critical uterine or neo  natal 
period. However, humans and wild animals 
are exposed simultaneously to various envi-
ronmental and food EDCs, generally at low 
levels, throughout their lives. Therefore, it 
would be valuable to determine the effects of a 
chronic exposure to low doses of EDCs on the 
reproductive axis and to identify the mecha-
nisms involved. In particular, it is not known 
whether lifetime exposures to low (environ-
mental) doses of estrogenic “feminizing” and 
antiandrogenic “demasculinizing” EDCs 
can have adverse effects on male reproduc-
tive function of the same magnitude as those 
of acute exposure to high non  environmental 
doses of these compounds in isolation.
In this study, we used a rat model of 
prolonged exposure to EDCs by gavage to 
determine the effects on male reproduction 
of two EDCs that may be associated in the 
human diet: the phytoestrogen genistein and 
the anti  androgenic fungicide vinclozolin. 
Genistein is an estrogenic iso  flavonoid found 
in leguminous plants (Breinholt et al. 2000). 
It is particularly abundant in diets contain-
ing soya or soya-derived products, leading 
to a dietary exposure of up to 2 mg/kg body 
weight/day; for infants fed milk formulas con-
taining soya, dietary exposure can reach 1 mg/
kg body weight/day (Setchell et al. 1998). 
In previous studies involving transient gesta-
tional, lactational, or adult intakes (Santti et al. 
1998), rodents have been exposed to various 
doses of genistein but the findings are equivo-
cal: some report male reproductive anoma-
lies (Wisniewski et al. 2003), whereas other 
do not (Faqi et al. 2004; Jung et al. 2004). 
Human exposure to genistein may affect the 
responsiveness and sensitivity to other xeno-
biotics, particularly environmental estrogenic 
chemicals (You et al. 2002) and other endo-
crine-active dietary contaminants. Vinclozolin, 
a dicarboximide fungicide extensively used on 
fruit and vegetables, is recognized as a human 
diet contaminant acting—essentially through 
its two main metabo  lites M1 and M2—as an 
androgen-receptor (AR) binding antago  nist 
(Kelce et al. 1994, 1997; Nellemann et al. 
2003). A recent French study reported that 
20% of 139 meal samples from work can-
teens contained measurable levels of vinclo-
zolin (Leblanc et al. 2000). In addition, assays 
of metabolites in urine revealed that > 80% 
of a population in central Italy was exposed 
to noticeable levels of vinclozolin and simi-
lar pesticides (Turci et al. 2006). Vinclozolin 
administered to experimental animals in vivo 
at various doses, by various routes, and for 
exposure periods (gestation, lactation, puberty, 
adulthood) produces a wide spectrum of 
reproductive defects: reduced anogenital dis-
tance (AGD); persistent nipples; cleft phallus; 
hypospadias; cryptorchidism; reduced weights 
of the ventral prostate, seminal vesicles, and 
epididymis; and reduced sperm counts (Gray 
et al. 1999; Monosson et al. 1999; Yu et al. 
2004). It is highly plausible that vinclozolin 
can induce such anomalies of the reproduc-
tive tract in humans (Kavlock and Cummings 
2005). However, most studies used doses 
100 times the U.S. Environmental Protection 
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Ba c k g r o u n d: The reproductive consequences and mechanisms of action of chronic exposure to 
low-dose endocrine disruptors are poorly understood.
oB j e c t i v e: We assessed the effects of a continuous, low-dose exposure to a phytoestrogen 
(genistein) and/or an antiandrogenic food contaminant (vinclozolin) on the male reproductive tract 
and fertility.
Me t h o d s : Male rats were exposed by gavage to genistein and vinclozolin from conception to adult-
hood, alone or in combination, at low doses (1 mg/kg/day) or higher doses (10 and 30 mg/kg/day). 
We studied a number of standard reproductive toxicology end points and also assessed testicular 
mRNA expression profiles using long-oligonucleotide microarrays.
re s u l t s: The low-dose mixture and high-dose vinclozolin produced the most significant alterations 
in adults: decreased sperm counts, reduced sperm motion parameters, decreased litter sizes, and 
increased post  implantation loss. Testicular mRNA expression profiles for these exposure conditions 
were strongly correlated. Functional clustering indicated that many of the genes induced belong 
to the “neuroactive ligand-receptor interactions” family encompassing several hormonally related 
actors (e.g., follicle-stimulating hormone and its receptor). All exposure conditions decreased the 
levels of mRNAs involved in ribosome function, indicating probable decreased protein production.
co n c l u s i o n s: Our study shows that chronic exposure to a mixture of a dose of a phyto  estrogen 
equivalent to that in the human diet and a low dose—albeit not environmental—of a common anti-
androgenic food contaminant may seriously affect the male reproductive tract and fertility.
key w o r d s : antiandrogen, endocrine disruption, male reproduction, mRNA, phytoestrogen, 
spermato  zoa, toxicology. Environ Health Perspect 117:1272–1279 (2009).  doi:10.1289/ehp.0800158 
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Agency (EPA) no observed adverse effect level 
(NOAEL) of 1.2 mg/kg body weight/day 
based on a combination of chronic toxicity, 
carcinogenicity, and reproductive toxicity in 
rats (U.S. EPA 2003).
To our knowledge, only one recent study 
has investigated the reproductive consequences 
(the frequency of hypospadias) of in utero 
exposure to both genistein and vinclozolin 
(Vilela et al. 2007). Using a life  long expo-
sure scheme, we found significant alterations 
of reproductive develop  ment and impair-
ment of several fertility end points by these 
compounds, the most severe effect resulting 
from combined exposure to a dietary level of 
genistein and a level of vinclozolin lower than 
the U.S. EPA-proposed NOAEL. In addition, 
we found that mRNA expression profiles in 
the adult testis are notably and differentially 
modified according to the exposure protocol. 
We also describe functional clustering of the 
genes affected into ontologic families.
Materials and Methods
Chemicals. Genistein with a purity of 99% 
was synthesized at the Laboratoire de Chimie 
Organique et Organométallique (Université 
Bordeaux 1, Talence, France). We extracted 
vinclozolin from the commercial formula-
tion Ronilan (BASF France, Levallois-Perret, 
France) according to Bursztyka et al. (2008). 
The extract was dried under vacuum and then 
recrystallized from methanol. Vinclozolin has a 
melting point of 108–109°C and its purity, as 
verified by HPLC-diode-array detection (from 
192 to 400 nm) and gas chromatography/
mass spectrometry analyses, was > 96% (data 
not shown). In addition, we tested the absence 
of the degradation products M1 and M2 by 
liquid chromatography/mass spectrometry as 
previously described (Bursztyka et al. 2008).
Doses used. The exposure scheme consisted 
of a “high” and a “low” dose for each com-
pound, and the corresponding combinations. 
The high doses we used were higher than the 
reported NOAEL of vinclozolin and the plau-
sible levels of genistein in the human diet; 
we chose these doses to be sufficiently low 
to maintain normal growth, as well as food 
and water intake. The genistein high dose, 
10 mg/kg body weight (G10), was greater 
than the genistein levels found in human diets 
in Southeast Asia (Tanaka et al. 2008) and 
was several times lower than the doses used 
in some reproductive studies; the low dose, 
1 mg/kg body weight (G1), was similar to 
that in soya-based diets (Tanaka et al. 2008). 
The vinclozolin high dose, 30 mg/kg body 
weight (V30), was substantially greater than 
real-life exposure levels but was 3–10 times 
lower than the doses used in several male 
reproductive studies (Gray et al. 2001). The 
acceptable daily intake (ADI) of vinclozo-
lin is 600 µg/day/person, corresponding to 
an exposure of 0.01 mg/kg body weight/day 
(Food and Agriculture Organization/World 
Health Organization 1998). In France, the 
estimated daily intake is 3.3 µg/kg/person 
(Leblanc et al. 2000), which is < 1% of the 
ADI. The low vinclozolin dose used in the 
present study, 1 mg/kg body weight (V1), was 
higher than human food contamination lev-
els; however, it was lower than the NOAEL 
combining chronic toxicity, carcinogenicity, 
and reproductive toxicity in rats (1.2 mg/kg 
body weight/day; U.S. EPA 2003).
Animals and regimens. A total of 80 spe-
cific-pathogen free (SPF) female and 32 SPF 
male Wistar Han rats at 8 weeks of age were 
purchased from Harlan France Sarl (Gannat, 
France) and fed with a soy-free diet (Harlan 
Teklad, Gannat, France). On their arrival, they 
were acclimatized to the animal facility con-
ditions (22°C with constant humidity and a 
12-hr light/dark period) for 4 weeks before 
mating. All animals were treated humanely 
and with regard for alleviation of suffering. 
They were maintained in accordance with the 
French Ministry of Agriculture guidelines for 
care and use of laboratory animals. From the 
acclimatization period, animals were fed a puri-
fied diet of pellets (18% casein, 46% starch, 
23% sucrose, 5% corn oil, 2% cellulose, 5% 
mineral mixture, and 1% vitamin mixture) and 
supplied with water ad libitum. dissolved in 
corn oil (Carrefour, Dijon, France) and admin-
istered by gavage (2 mL/kg body weight). 
Control animals were treated with the vehicle 
alone. Animals were identified by a unique ear 
tag with a randomly assigned number.
Exposure conditions. We randomly 
assigned 10 females to each treatment group 
and mated them with male rats (five females 
and two males per cage) with the aim of 
obtaining at least 20 adult male offspring per 
treatment group for subsequent data compari-
sons and analyses. We examined females daily 
and caged them separately when a vaginal 
sperm plug was observed [defined as gesta-
tional day (GD) 1]. From GD1 until weaning 
[post  natal day (PND) 21], the dams were 
gavaged daily with the chemical preparations 
and then killed under anesthesia. On the day 
of parturition, all litter sizes were standardized 
to 10 offspring. From weaning (PND21) to 
adulthood (PND80), all animals were gav-
aged daily according to the various exposure 
protocols, and every 4 days they were weighed 
and inspected for anomalies.
Reproductive development end points. On 
PND25, we randomly selected five males from 
each group; the AGD was meas  ured with a dig-
ital caliper, and the development of the penis 
was scored according to the procedure reported 
by Maeda et al. (2000). For both tests, the 
operator was blind to the treatment group.
F1 mating and fertility end points. On 
PND80, six males per group were selected 
for mating with new unexposed acclima-
tized females (Harlan France Sarl); each male 
was housed with one female for 4 days. As 
described above, females were inspected daily; 
when a vaginal sperm plug was found, females 
were housed separately until parturition. We 
used the following fertility end points: mating 
index (number of mated females ÷ number of 
females cohabited with males × 100), fertility 
index (number of pregnant females ÷ num-
ber of mated females × 100), litter size, mean 
weight per neonate, sex ratio at birth, and per-
centage of post  implantation loss (number of 
embryonic scars ÷ number of embryonic but-
tons and scars × 100).
Sacrifice. On PND85, we anesthetized 
males using isoflurane (2.5%) and collected 
blood under heparin conditions from the 
dorsal aorta for subsequent hormonal tests. 
Animals were killed by thoracic cage opening. 
For each animal, both testes, epididymides 
and the seminal vesicles, ventral prostate, and 
liver were excised and trimmed of fat. We 
then weighed the tissues (Precisa model 125A; 
Precisa, Poissy, France) and calculated relative 
weights (weight of the organ in grams per 
kilogram body weight).
Sperm motility and motion characteristics. 
Immediately after epididymis separation, we 
excised approximately a 0.8-cm portion of the 
proximal part of the vas deferens and placed 
it in a Petri dish containing 4 mL of pre-
warmed M199 medium (Gibco BRL, Paisley, 
Scotland) supplemented with 1% bovine 
serum albumin (Sigma-Aldrich, Saint-Quentin 
Fallavier, France). After incubating for 5 min 
at 37°C, we swirled the Petri dish to facilitate 
the spontaneous release of sperm from the vas 
deferens. We loaded 10 µL sperm suspension 
into an 80-µm-deep, 2X-Cel disposable sperm 
analysis chamber (Hamilton-Thorne Research, 
Beverly, MA, USA). The device was placed 
on the heated stage (37°C) of a computer-
aided sperm analysis (CASA) integrated visual 
optical system (Hamilton-Thorne Research). 
The acquisition parameters and rates used for 
analysis were those of standard rat analysis 
setup 1 (frame rate, 60 Hz; frames acquired, 
30; minimum cell size, 7 pixels; minimum 
contrast, 15; brightness, 2,500). Sperm were 
considered motile if the average path velocity 
(VAP) exceeded 20 µm/sec and were consid-
ered progressively motile when VAP exceeded 
50 µm/sec and straightness of trajectory (STR) 
exceeded 80%. We analyzed a minimum of 
200 motile sperm from each animal for the fol-
lowing variables: percentage of motile sperm, 
percentage of progressively motile sperm, VAP 
(micrometers per second), straight-line veloc-
ity (VSL; micrometers per second), curvilinear 
velocity (VCL; micrometers per second), lat-
eral head displacement (ALH; micrometers), 
beat cross frequency (BCF; Hz), STR (%), 
and linearity of   trajectory (LIN; %).Eustache et al.
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Epididymal sperm number. The proce-
dure used for assessing the sperm number in 
the cauda epididymis was based on specific 
staining of sperm DNA and counting with 
the CASA instrument (Strader et al. 1996). 
We dissected out the cauda epididymis just 
below the point at which the vas deferens 
joins the epididymis at the distal corpus and 
at the boundary between the corpus and the 
proximal end of the cauda epididymis. The 
tissue was placed in a 50-mL plastic conical 
tube, chopped finely with scissors, and mixed 
with 25 mL physiological buffered saline plus 
0.05 g/100 mL Triton X-100. The preparation 
was then crushed with an Ultra Turax T25 
basic homogenizer (24,000 rpm 3 × 1 min; 
IKA, Staufen, Germany) The cauda epididymis 
preparation was stored frozen at –20°C. On 
the day of the sperm number assessment, 
we thawed the preparation, added 0.2-mL 
aliquots to vials containing the fluorescent 
DNA-specific dye bisbenzimide (Ident stain; 
Hamilton-Thorne Research, Danvers, MA, 
USA), and vortexed it for 30 sec. Following 
the manufacturer recom  mendations, we 
stained the sperm for 2 min. The prepara-
tion was vortexed again, immediately loaded 
into a standard-count disposable 20-µm 
analysis chamber (Leja, Nieuw-Vennep, the 
Netherlands), and placed on the CASA stage. 
The sperm heads were clearly illuminated 
under an ultra  violet beam, identified (and 
debris ignored), and automatically counted 
in 10 fields using the RAT-IDENT mode of 
the CASA instrument. The data are expressed 
as the total number of spermatozoa per cauda 
epididymal tissue sample.
Histology. One testis and one epididymis 
per animal were fixed in 4% formaldehyde 
(Sigma-Aldrich), embedded in paraffin, cut 
into 4 µm-thick sections, stained with hema-
toxylin and eosin (Sigma-Aldrich), and exam-
ined under light microscopy.
Assays for plasma luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), tes-
tosterone, and estradiol. One plasma sample 
per animal was frozen at –20°C until assayed. 
LH and FSH reagents (AH R002 and AH 
R004, respectively, from Biocode-Hycel) were 
supplied by OSTEOmedical GmbH (Bünde, 
Germany). The principle of the rat LH assay 
is based on competition between the LH of 
the rat sample and a 125I-labeled rat LH tracer 
for binding to a highly specific rabbit poly-
clonal anti  body. The sensitivity of this assay is 
0.14 ng/mL. The rat FSH assay is a solid-phase 
immuno  radiometric assay offering high affinity 
and specificity for two different epitopes on rat 
FSH. The sensitivity of the assay is 0.2 ng/mL. 
We determined total testosterone and estradiol 
using the COAT-A-COUNT testosterone and 
estradiol radioimmunoassays (DPC France, La 
Garenne Colombes, France) according to the 
manufacturer’s protocols. The detection limits 
of the assays were 0.2 ng/mL and 2 pg/mL, 
respectively. All hormone concentrations were 
determined in duplicate.
RNA preparation and microarrays. We 
prepared RNA from individual testes obtained 
from six animals in each group. RNA was 
quantified and the quality evaluated using a 
2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, USA). The RNA integrity numbers for 
all RNAs were > 8. Pools of RNAs from six 
testes were prepared with strict equilibration of 
their quantity to ensure equal representation of 
each individual RNA. After quality control, we 
sent the samples to the micro  array platform of 
NimbleGen (Reykjavik, Iceland). NimbleGen 
rat microarrays cover 23,456 transcripts rep-
resented by eight 60-mer oligo  nucleo  tides 
spotted in duplicate on the glass slide. The 
oligo  nucleotides are iso  thermic, which allows 
hybridization at a high temperature acceptable 
for the complete set of transcripts (70°C). The 
correlation between the homologous oligo-
nucleotides in each hybridization was > 0.99. 
Table 1. Developmental anomalies, incidence of reproductive malformations, and reproductive organ weights in adult rats.
  Treatment
Observation  Control  G1  G10  V1  V30  G1 + V1  G10 + V30
Development
  Anogenital distance [mean ± SD (mm)]a  19.4 ± 0.8  20.0 ± 1.1  19.7 ± 0.9  17.8 ± 0.7*  17.5 ± 0.7*  17.8 ± 0.7*  18.0 ± 1.0
  Immature penile developmenta  1/5  1/5  5/5  5/5  2/5  4/5  2/5
  Hypospadias (%)  0 (0)  0 (0)  0 (0)  0 (0)  7 (24)  0 (0)  2 (10)
  Cryptorchidism (%)  1 (4)  1 (4)  3 (13)  0 (0)  3 (10)  1 (5)  0 (0)
  Epididymal anomalies (%)b  0 (0)  1 (4)  0 (0)  1 (4)  1 (3)  4 (19)  0 (0)
  Other (%)  0 (0)  0 (0)  0 (0)  1 (4)c   2 (7)d   0 (0)  1 (5)e
  Overall incidence of anomalies (%)  1 (4)  2 (8)  3 (13)  2 (8)  13 (44)  5 (24)  3 (15)
Organ weight (mean ± SE)
  Body (g)  309 ± 7  350 ± 7#  333 ± 6**  327 ± 8  320 ± 5  322 ± 9  335 ± 6#
  Testisf  9.7 ± 0.3  9.8 ± 0.2  9.9 ± 0.3  9.9 ± 0.3  10.0 ± 0.3  9.7 ± 0.4  10.6 ± 0.2#
  Epididymisf  1.56 ± 0.07  1.30 ± 0.03#  1.36 ± 0.07#  1.32 ± 0.05#  1.21 ± 0.09#  1.16 ± 0.06#  1.30 ± 0.04#
  Seminal vesiclesf  3.54 ± 0.26  3.26 ± 0.18  3.24 ± 0.20  3.20 ± 0.15  2.78 ± 0.11#  2.93 ± 0.12**  2.93 ± 0.17**
  Ventral prostatef  2.28 ± 0.14  2.19 ± 0.09  2.14 ± 0.13  2.08 ± 0.11  1.90 ± 0.07**  2.22 ± 0.14  1.92 ± 0.11**
  Liverf  30.9 ± 0.7  31.7 ± 0.8  33.1 ± 0.5**  30.8 ± 0.6  31.5 ± 0.7  28.9 ± 0.7*  30.9 ± 0.5
aMeasurements and observations on PND25 for five randomly selected animals from each group. bMacroscopically irregular, cystic, and/or enlarged epididymis. cMicropenis. dTwo pups 
from the same litter had multiple anomalies: sexual ambiguity, abnormal seminal vesicles, and absence of vas deferens. eSexual ambiguity. fRelative weights (g/kg). *Tendency, but not 
significant (p < 0.10). **p < 0.05, and #p < 0.01 compared with controls. 
Figure 1. Box plot displaying 10th, 25th, 50th, 75th, and 90th percentile values, and the mean value (thick line) of sperm progressive motility (A), STR (B), and VCL 
(C) in rats on PND80. 
**p < 0.05, #p < 0.01, ##p < 0.005, and †p < 0.001, compared with controls. 
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We used Cluster 3 (Eisen et al. 1998) and 
Treeview (Saldanha 2004) for expression clus-
tering, and DAVID software (Dennis et al. 
2003) for functional clustering. 
Quantitative reverse-transcriptase poly-
merase chain reaction (qRT-PCR) validation 
and inter  individual variation. We performed 
qRT-PCR for 10 genes using cDNA prepared 
from four individual testes [four animals in 
each category; PCR primers are described 
Supplemental Material, Table 2 (doi:10.1289/
ehp.0800158.S1/)]. The reactions were car-
ried out in a 15-µL volume using a Roche 
Lightcycler (Roche, Meylan, France) and an 
Invitrogen Sybergreen quantitative PCR kit 
(Invitrogen, Cergy-Pontoise, France). After 
2 min at 50°C and 2 min at 94°C, each reac-
tion was carried out for 40 cycles (94°C for 
10 sec, 55°C for 20 sec, and 72°C for 20 sec 
when fluorescence was meas  ured). This was 
followed by progressive melting by increas-
ing the temperature from 60°C to 99°C over 
10 min, with continuous fluorescence cap-
ture. We considered the resulting melting 
curve satisfactory if one peak only was visible 
on its derivative. In addition, PCR products 
were subjected to electrophoresis on an aga-
rose gel to check for a single product of the 
expected size.
Data analysis. Statistical tests were carried 
out using BMDP statistical software, version 2 
for Windows (Dixon 1988). We determined 
statistical significance of quantitative differ-
ences between treated groups and controls and 
between treatment modalities using post hoc 
Tukey’s pairwise comparisons after an analysis 
of variance. For visual clarity in the tables and 
figures, we present only the significant dif-
ferences between each compound or mixture 
exposure modality and controls. Only pairwise 
significant differences in the various treatment 
modalities are reported in text. Differences for 
qualitative variables between treatment and 
control groups were tested using the Pearson 
chi-square test. The significance level is set at 
0.05. However, for some aspects of the study 
(as indicated in tables and figures), we used 
a threshold of 0.10 because of the relatively 
small size of the groups. For several figures in 
both the article and the Supplemental Material 
(doi:10.1289/ehp.0800158.S1), we present 
box plots (rather than standard histograms 
showing only mean and SE values) in order 
to present the distributions observed for each 
exposure group and therefore the true level of 
variability.
Results
Developmental anomalies and body and organ 
weights. The observed anomalies of the exter-
nal genitalia are summarized in Table 1. Penile 
development was immature in all groups 
except G1, V30, and G10 + V30. Overall, we 
found the highest rates of genitalia anomalies 
for the low-dose mixture, G1 + V1, and high-
dose vinclozolin, V30. The body weights and 
relative organ weights in control and treated 
animals on PND80 are presented in Table 1. 
The gain in body weight was unaffected by 
any treatment (data not shown). The relative 
liver weight was significantly different from 
control only for G10 (Table 1) and did not 
vary significantly among the different expo-
sure groups studied. The relative epididymal 
weight was significantly lower in all treated 
groups compared with controls (Table 1) and 
significantly lower in the low-dose mixture 
(G1 + V1) compared with V1 (p < 0.05). 
Relative testis weights were significantly higher 
in the high-dose mixture than in the low-dose 
mixture (p < 0.01). The relative prostate and 
seminal vesicle weights were decreased with 
V30 compared with controls. In these cases, 
the addition of genistein had no influence. 
For these organs, we found no significant dif-
ference between all the groups exposed to the 
compounds.
Sperm motility and kinematic characteris-
tics. All kinematic characteristics, except for 
the amplitude of ALH and LIN, were sig-
nificantly altered in the treated animals. The 
VCL was significantly lower in all exposure 
groups than in controls, whereas the percent-
age of progressively motile sperm and the 
STR were significantly lower in all treated 
groups except G10 than in controls [Figure 1; 
see also Supplemental Material, Table 1 
(doi:10.1289/ehp.0800158.S1)].
Epididymal sperm number. The sperm 
reserve in the cauda epididymis was signifi-
cantly lower than control values for G10, 
V30, G1 + V1, and G10 + V30, (Figure 2), 
and it was significantly lower for the low-
dose mixture than for G1 or V1 alone (both 
p < 0.005). We observed the smallest mean 
value for the low-dose mixture (58 ± 11 vs. 
104 ± 14 × 106 spermatozoa in the control; 
p = 0.02), which was not significantly differ-
ent from that found for V30.
Histology. Treatment had no obvious effect 
on testis and epididymis anatomy. However, 
we observed small variations in tissue/organ 
histology [see Supplemental Material, Figure 1 
(doi:10.1289/ehp.0800158.S1)].
Hormone concentrations. On PND80, 
mean FSH concentrations were significantly 
higher for G1 + V1, G10 + V30, and V30 
than for control groups [13.0 ± 5.1, 11.6 
± 2.0, and 12.3 ± 4.3 vs. 9.9 ± 2.5 ng/mL, 
respectively; all p < 0.05; see Supplemental 
Material, Figure 2 (doi:10.1289/ehp.0800158.
S1)]. Mean estradiol concentrations were sig-
nificantly lower than control values only in 
the G1 + V1 group (3.7 ± 3.9 vs. 6.1 ± 3.6 pg/
mL; p < 0.05; see Supplemental Material, 
Figure 2). Testosterone levels were signifi-
cantly lower than controls in the G10 + V30 
and G10 groups (2.0 ± 1.7 and 2.4 ± 2.6 vs. 
4.0 ± 3.2 ng/mL; both p < 0.05). The LH con-
centration tended to be higher than control 
values only in the V30 group (1.34 ± 0.81 vs. 
0.97 ± 0.99; p = 0.07).
Mating and fertility. Table 2 summarizes 
the fertility of the exposed male rats crossed 
with non  exposed females. The mating index 
was markedly but not significantly lower with 
the low-dose mixture compared with the con-
trol and the other exposure groups. Litter 
sizes were significantly smaller in the G1 + 
V1, G10 + V30, G1, and G10 groups; the 
smallest litters were in the low-dose mixture 
group (5.3 ± 1.5 vs. 13.0 ± 1.6 in controls; 
Figure 2. Box plot displaying 10th, 25th, 50th, 75th, 
and 90th percentile values and the mean value 
(thick line) of epididymal (cauda) sperm number in 
rats on PND80. The most pronounced differences 
in sperm count compared with controls were in the 
V30 and G1 + V1 groups. 
**p < 0.05 compared with controls. 
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Table 2. Effects of treatments on mating and fertility in adult rats at PND80.
  Treatment
Characteristic  Control  G1  G10  V1  V30  G1 + V1  G10 +V30
Mating index (%)a  83  100  83  67  83  50  83
Fertility index (%)b  100  100  100  100  80  100  100
Litter size  13.0 ± 1.6  7.3 ± 4.0**  7.8 ± 2.9#  11.3 ± 0.5*  7.5 ± 4.1  5.3 ± 1.5**  8.8 ± 2.8**
  (mean ± SD)
Pup weight  5.6 ± 0.4  6.2 ± 0.7*  6.2 ± 0.6  5.6 ± 0.3  5.9 ± 0.3  6.5 ± 0.4**  6.1 ± 1.1
  (mean ± SD)
Sex ratio at birthc  0.508  0.591  0.436  0.644  0.663  0.625  0.455
Postimplantation loss (%)  1.5  8.2*  12.5  9.8*  44.4 d #  10.5*  13.5**
aNumber of mated females/number of females × 100. bNumber of pregnant females/number of mated females × 100. cTotal 
number of males/total number of pups. dHigh value mainly due to one female with no pups but 11 implantation sites.
*Tendency, but not significant (p < 0.10). **p < 0.05, and #p < 0.01 compared with controls. Eustache et al.
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p < 0.05). Litter sizes did not differ signifi-
cantly among the various exposure groups. 
The post  implantation loss was significantly 
higher in the V30 and the G10 + V30 groups 
than in the control group.
Testis transcriptome analysis. The effects 
of the different treatments on gene repression/
induction were strikingly different. Applying 
a 2-fold threshold, genistein had a generally 
repressive effect on gene expression in the tes-
tis, particularly at the low dose; the high vin-
clozolin dose (but not the low dose) had the 
opposite effect (Figure 3). The array results 
were validated by qRT-PCR with a sample of 
10 genes [see Supplemental Material, Table 2 
(doi:10.1289/ehp.0800158.S1)]; consistent 
with other results obtained with NimbleGen 
arrays (Buffat et al. 2007), the correlation 
between the array and the qRT-PCR was > 0.8. 
Using the complete data set, and no thresh-
olds, the strongest correlation was between 
G1 + V1 and V30 [r = 0.82; see Supplemental 
Table 3 (doi:10.1289/ehp.0800158.S1); see 
also Figure 3]. This is in good accordance with 
the phenotypic observations: V30 and G1 + 
V1 had very similar effects on several mark-
ers. Nonsupervised hierarchical classification 
(Figure 4) showed perfectly correlated dupli-
cates and illustrated the clustering of the genes 
modified by V30 and V1 + G1. This approach 
identified seven clusters of genes (Figure 4). 
Functional classi  fi  cation of the genes enabled 
us to identify biological functions for each 
sub  cluster (Table 3); we functionally analyzed 
each sub  group of genes using DAVID, after 
elimination of poorly annotated factors and 
olfactory receptor genes that are always highly 
represented in rodent micro  arrays. Among the 
genes significantly clustered in KEGG (Kyoto 
Encyclopedia of Genes and Genomes) path-
ways, some were involved in regulation of insu-
lin pathways (cluster 1); others were involved 
in fructose and glucose metabolism (cluster 2). 
Clusters 3 and 4 comprised genes involved 
in inter  actions between ligands and receptors 
(e.g., dopamine, acetyl  choline, histamine, 
parathyroid hormone, prostanoids), with the 
similar composition of the two clusters indi-
cating a quantitative rather than a qualitative 
effect. The same applies to clusters 5 and 6, 
which were highly enriched in genes encoding 
ribosomal proteins. These genes were strongly 
down-regulated by all treatments except low 
doses of genistein. This may signify a slowing 
down of protein synthesis after exposure to the 
compounds. Finally, cluster 7 was function-
ally clustered but with relatively low statistical 
significances, and included mainly genes of 
the gonadotropin-releasing hormone pathway. 
We observed the major effect on these genes 
(up-regulation) in the G1 and G10 groups.
Discussion
Our study provides evidence that lifelong expo-
sure to low-dose genistein and/or vinclozolin 
results in a number of anomalies of the male 
reproductive tract and fertility. This markedly 
contrasts with previous reports based on short 
windows of exposure to these compounds, 
whether gestational, neonatal, or during the 
puberty/adult periods, showing only mild or 
no reproductive alterations [see Supplemental 
Material, Table 4 (doi:10.1289/ehp.0800158.
S1)]. Interestingly, in the adult, despite the 
absence of macroscopic and microscopic modi-
fications of the testis, we found various changes 
of the testis transcriptome for all exposure pro-
tocols. Furthermore, the intriguing similarities 
of the phenotypes/genotypes of the animals 
exposed to high-dose vinclozolin and those 
exposed to the low-dose mixture, which proba-
bly depend on complex modes of action in this 
chronic exposure from conception to adult-
hood, may suggest an anti  androgenic action of 
genistein at a low dose when combined with 
low-dose vinclozolin (with a possible “synergis-
tic” action because each compound taken alone 
at a low dose had no or a weak effect). By con-
trast and for several phenotypes (epididymis, 
seminal vesicle, and ventral prostate relative 
weights, as well as litter size), the effect of the 
high-dose mixture appeared milder than the 
effect of high-dose vinclozolin alone. This 
could suggest that, in these specific cases, a 
“high” dose of genistein could attenuate the 
effects of vinclozolin. Finally, consistent with 
these observations, the effects observed for sev-
eral end points were more pronounced with 
the low-dose mixture than with the high-dose 
mixture. Obviously our comments are purely 
speculative because of the descriptive design 
of the study, which warrants further work to 
approach the underlying molecu  lar bases of 
these intriguing results.
Phenotype modifications with F1 vinclozo-
lin exposures. At a vinclozolin dose of 30 mg/
kg body weight, we observed a rate of develop-
mental anomalies of the reproductive tract that 
are consistent with the higher rate previously 
reported (Gray et al. 2001); this validates our 
exposure protocol. At this dose, we also found 
some of the more detrimental effects on fertil-
ity, including a high rate of post  implantation 
loss (note that this end point was also high 
for the 1 mg/kg vinclozolin dose). High-dose 
vinclozolin caused a significant increase in the 
FSH concentration, suggesting a direct effect 
on the pituitary axis according to Nellemann 
et al. (2003). The diminished fertility, evi-
denced by the reduced litter size, especially 
with the high dose, could be due, at least in 
part, to decreased sperm production and motil-
ity. It could also be partly the consequence of 
the marked effects of vinclozolin on sperm 
chromatin we reported previously (Auger 
et al. 2004). Prenatal plus infantile exposure 
of male rabbits to 7.2 mg/kg/day vinclozo-
lin increases the amount of morphologically 
abnormal spermatozoa, mostly due to nuclear 
and acrosomal defects (Veeramachaneni et al. 
2006). These anomalies may result in impair-
ment of the fertilizing ability, embryonic 
development, or both (Bartoov et al. 2001; 
Figure 3. Number of testicular genes modified by 
the various exposures. C, control. The threshold 
relative to the controls was > 2. 
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Table 3. Gene representation and main KEGG pathways identified in the groups defined after the hierarchical clustering of the data from testis cDNA.
      No. of genes  No. of
  No. of  No.   (excluding ill-  olfactory-receptor–      Secondary
Cluster   transcripts  of genes  characterized genes)a  encoding genes (%)  Main KEGG pathway  p-Value  KEGG pathway  p-Value
Group 1  9,401  8,739  5,200  115 (1.2)  Insulin signaling  5.0 × 10–3
Group 2  522  494  369  4 (0.8)  Fructose and mannose metabolism  9.5 × 10–4  Neoglucogenesis  1.5 × 10–3
Group 3  2,481  2,405  1,422  268 (10.8)  Neuroactive ligand/receptor interaction  5.4 × 10–13  Calcium signaling  2.6 × 10–4
Group 4  2,801  2,695  1,521  684 (24.4)  Neuroactive ligand/receptor interaction  3.0 × 10–25  Calcium signaling  1.6 × 10–6
Group 5  1,123  1,076  815  3 (0.3)  Ribosome  4.3 × 10–14
Group 6  469  431  431  4 (0.9)  Ribosome  1.4 × 10–9
Group 7  6,096  5,727  3,788  200 (3.2)  GnRH signaling pathway  1.0 × 10–3  Colorectal cancer  4.3 × 10–3
              Renin–angiotensin system  1.2 × 10–2
              MAPK signaling  1.2 × 10–2
Abbreviations: GnRH, gonadotropin-releasing hormone; MAPK, mitogen-activated protein kinase.
aExcluding genes labeled LOC or RGD. Male reproduction and exposure to genistein and vinclozolin
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Sailer et al. 1996). Whatever the period of 
exposure, most published studies involving 
low-dose vinclozolin report marginal or no 
effects [see Supplemental Material, Table 4 
(doi:10.1289/ehp.0800158.S1); Colbert et al. 
2005; Gray et al. 1999; Hellwig et al. 2000; 
Shin et al. 2006], contrary to the significant 
adverse reproductive effects observed at high 
doses (Yu et al. 2004). Studies of rats exposed 
to vinclozolin have nevertheless revealed that 
dose–response relationships are not equiva-
lent among end points (National Toxicology 
Program 2001). AR expression in the male 
reproductive system of the rat varies according 
to time and cell type, such that the effects of 
vinclozolin may vary substantially according 
to developmental period(s) and duration of 
exposure. Indeed, some of the adverse effects 
observed in adults may depend on changes in 
AR expression related to the continuous expo-
sure. In this respect, the pheno  typic changes 
we observed with vinclozolin exposure were 
not necessarily induced only in utero or during 
the early neonatal period. In addition, they 
could have been mediated by as yet unde-
scribed actions of vinclozolin, or its metabo-
lites, independent of antagonistic action on 
ARs.
Phenotype modifications with F1 genistein 
exposures. Chronic exposure to dietary levels 
of genistein, from conception to adulthood, 
may have deleterious effects on male reproduc-
tive development, adult reproductive organs, 
and fertility. Some of our findings were in 
accordance with previous studies: the penis 
immaturity we observed on PND25 in the 
G10 group is similar to the delayed prepu-
tial separation after gestational and lactational 
exposure to 5 mg/kg genistein in the diet in 
Long-Evans rats (Wisniewski et al. 2003) and 
decreased plasma testosterone (for the “high” 
dose only) reported by Weber et al. (2001) 
for a similar dose. This result of Weber et al.
(2001) reinforces the idea that genistein 
decreases the steroidogenic response of Leydig 
cells, which express both estrogen receptor 
(ER) α and ERβ, although the expression of 
these ERs was not affected in our array experi-
ments. Svechnikov et al. (2005) reported that 
dietary genistein down-regulates an early step 
of testosterone synthesis (expression of mito-
chondrial P450 side-chain cleavage enzyme, 
which catalyses the conversion of cholesterol 
to pregnenolone). However, as in the study of 
Roberts et al. (2000), the testosterone levels we 
found with G1 were not significantly abnor-
mal, suggesting that the effect of genistein on 
Leydig cells may be dose dependent; consis-
tent with this notion, at the doses and with the 
strain we used, no difference was detectable in 
our microarray experiment.
Several of the adverse effects we observed 
are indisputably related to the estrogen agonist 
activity of genistein and the localization of both 
types of ERs that are expressed at various levels 
in male rat reproductive organs (Boukari et al. 
2007; Mäkelä et al. 2000; Pelletier et al. 2000). 
The lower reproductive performance observed 
here probably results in part from the combi-
nation of sperm movement anomalies for the 
low- and high-dose exposures and the reduced 
epididymal reserve (only for G10). Genistein 
decreases sperm motion variables in vitro by 
inhibiting the sperm protein kinase (Bajpai and 
Doncel 2003), which our microarray experi-
ments showed to be slightly decreased (reduced 
to 0.76 for G1). Moreover, genistein has 
been reported to inhibit α-glucosidase, which 
is known to sustain sperm motility (Lee and 
Lee 2001); the expression of this enzyme was 
also slightly reduced by G1 in our experiment 
(× 0.78). To our knowledge, the increased 
post  implantation loss we describe has not pre-
viously been reported. However, similar repro-
ductive anomalies have recently been reported 
for CD-1 mice after neonatal exposure to 
genistein at environmentally relevant doses 
(Jefferson et al. 2005), and the reported geno-
toxicity of genistein may be involved (Stopper 
et al. 2005). Genistein is a topo  isomerase II 
inhibitor (Markovits et al. 1989), but we did 
not find any modification of the expression of 
the corresponding gene in the testis. Another 
important consequence of the lifelong genistein 
exposure was the high incidence of reproduc-
tive effects, and this contrasts strongly with the 
absence of effects reported for shorter gesta-
tional/lactational, puberty/adult exposures [see 
Supplemental Material, Table 4 (doi:10.1289/
ehp.0800158.S1)]. The possible potentiation 
of the effects of vinclozolin by exposure to low-
dose genistein that we report here might be 
relevant for human risk assessment because of 
the similar exposure conditions.
Phenotype effects of the F1 exposures to the 
mixtures: similarities of the effects with the 
low-dose mixture and high-dose vinclozolin. 
In our experimental conditions, the type and 
magnitude of effects of the low-dose mixture 
were close to those of high-dose vinclozolin 
alone. Low combined doses of genistein and 
vinclozolin significantly increased FSH levels 
and decreased estradiol levels, an effect very 
similar to that of high-dose vinclozolin alone. 
This result parallels the similarities between 
the effects of the low-dose mixture and the 
high-dose vinclozolin on sperm production, 
motility, and kinematics and on the weights 
of the epididymis and seminal vesicles. 
These various similarities evoke a synergistic 
androgenic effect with the low-dose mixture. 
Genistein has been reported to exhibit in vitro 
anti  androgenic activity in addition to its well-
established estrogenic activity (Rosenberg 
Zand et al. 2000). This type of mechanism 
may act in vivo and contribute to some of 
the anti  androgenic demasculinizing effects 
observed here with the low-dose mixture, 
with a magnitude similar to that found for 
high-dose vinclozolin (the effects found with 
both exposure modalities, G1 + V1 and V30 
were not significantly different for most of 
the end points studied). Consistent with this 
notion, combinations of antiandrogens at 
NOAEL doses have been induced significant 
synergistic effects in vivo (Hass et al. 2007; 
Kortenkamp 2008). However, more complex 
Figure 4. Nonsupervised hierarchical classification 
revealing seven gene clusters according to the 
various exposure protocols. C, control. A num-
ber of genes were down-regulated by G1 rela-
tive to the control (cluster 1). Cluster 2 includes 
genes induced by G10 and by G10 + V30. Cluster 3 
genes were weakly induced by G1 + V1, V1, and 
V30. Some genes were induced by all the treat-
ments, especially by G1 + V1 and V30 (cluster 4). 
Cluster 5 contains genes strongly expressed in the 
control and not modified by G1, all other treatments 
decreasing their expression. Several genes in clus-
ter 6 were induced specifically by G1. Cluster 7 
consists of essentially genes weakly induced by 
G1 and G10. 
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modes of actions cannot be ruled out because 
of our continuous exposure modalities and the 
multiple biological activities of both the com-
pounds. The complex transcriptomic modifi-
cations caused in the adult testis illustrate this. 
Indeed, although the effect on gene induction 
of the high vinclozolin dose is generally stron-
ger than that of the combination of genistein 
and vinclozolin, the overall effect is very simi-
lar. As a consequence, the pheno  typic altera-
tions may be very similar, even if the effects of 
the low-dose combination only seldom attain 
the 2× threshold.
Testis transcriptome alterations and the 
phenotypes observed. The gene expression pro-
file under the influence of the EDCs genistein 
and vinclozolin can be summarized as follows 
(Figure 4). Genistein administered alone at a 
low dose had the smallest effects of all treat-
ments tested. The alterations were minor, 
despite 1,089 genes being down-regulated 
(using a 2× threshold). This can be explained 
by the strong and exclusive deregulation of 
a particular cluster of genes (cluster 4), with 
most other clusters very similar to the controls. 
Cluster 4 is composed of genes involved in 
ligand/receptor interactions, involving numer-
ous hormone peptides and G-protein–coupled 
receptors. At a higher dose of genistein, with 
or without high-dose vinclozolin, the altera-
tions were greater. Presumably, the effects 
of genistein mask the putative effects of vin-
clozolin, probably indicating that high doses 
of genistein are the driving force in the gene 
expression regulation.
The effects of vinclozolin at low and high 
doses were similar and were strongly correlated 
with the effects of the low-dose mixture. This 
suggests that the low genistein dose is able to 
potentiate the effects of vinclozolin. One pos-
sible mechanism is activation by genistein of 
specific receptors of protein ligands induced 
by low-dose vinclozolin, and specific prepara-
tion of the chromatin to bind specific tran-
scription factors. One of the candidates for 
such an effect is the gene Cbx3 (Chromobox, 
3 homolog), whose protein has a chromo-
domain able to regulate chromatin dynamics 
toward gene induction or repression (Benetti 
et al. 2007).
Conclusion
A continuous exposure to low combined 
doses of genistein and vinclozolin affects male 
reproductive health by inducing reproductive 
developmental anomalies, alterations in sperm 
production and quality, and fertility disorders. 
The long-term deleterious consequences of 
chronic exposures to a low-dose mixture of 
genistein/vinclozolin suggest complex modes of 
action; we are currently investigating this issue 
further. Transcriptome analysis may uncover 
specific factors with potentially major effects 
on numerous gene targets, such as Cbx3.
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